S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:AXSM

Axsome Therapeutics Price Target, Predictions & Analyst Ratings

$33.40
+0.44 (+1.33 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$32.54
$34.41
50-Day Range
$19.91
$57.11
52-Week Range
$19.38
$87.24
Volume986,614 shs
Average Volume668,646 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Axsome Therapeutics (NASDAQ:AXSM) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 13 Analyst Ratings

Analyst Price Target Consensus

$103.65

High PT$180.00
Average PT$103.65
Low PT$34.00
TypeCurrent
9/24/20 to 9/24/21
1 Month Ago
8/25/20 to 8/25/21
3 Months Ago
6/26/20 to 6/26/21
1 Year Ago
9/25/19 to 9/24/20
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$103.65$107.40$130.86$149.56
Price Target Upside210.32% Upside132.61% Upside93.12% Upside72.29% Upside
Get Axsome Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Axsome Therapeutics (NASDAQ:AXSM) vs. Its Competitors

TypeAxsome TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.77
2.73
2.56
Consensus RatingBuyBuyBuy
Price Target Upside125.84% Upside7.78% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
372
71.54%
Underperform Votes
148
28.46%
Avg. Outperform Votes
178
67.42%
Avg. Underperform Votes
86
32.58%
Avg. Outperform Votes
829
69.49%
Avg. Underperform Votes
364
30.51%

Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/15/2021HC Wainwright
Ram Selvaraju
Reiterated RatingBuy$180.00+549.12%
8/27/2021William Blair
Reiterated RatingBuy
8/23/2021Mizuho
Reiterated RatingBuy$55.00+135.45%
8/10/2021BTIG Research
Robert Hazlett
Lower Price TargetBuy ➝ Buy$123.00 ➝ $55.00+131.29%
8/10/2021SVB Leerink
Lower Price TargetPositive ➝ Outperform$115.00 ➝ $75.00+208.01%
8/10/2021Truist
Joon Lee
Lower Price TargetBuy$200.00 ➝ $160.00+568.62%
8/10/2021Truist Securities
Lower Price TargetBuy$200.00 ➝ $160.00+565.56%
8/10/2021Morgan Stanley
DowngradeOverweight ➝ Equal Weight$105.00 ➝ $34.00+24.22%
6/10/2021Berenberg Bank
Initiated CoverageBuy$112.00+76.38%
1/8/2021Jefferies Financial Group
Initiated CoverageBuy$129.00+65.79%
12/31/2020UBS Group
Reiterated RatingPositive
12/3/2020Cantor Fitzgerald
Boost Price TargetPositive ➝ Overweight$131.00 ➝ $161.00+117.69%
9/29/2020Bank of America
Initiated CoverageUnderperform$66.00-13.68%
4/28/2020Guggenheim
Yatin Suneja
Boost Price TargetIn-Line ➝ Buy$158.00 ➝ $200.00+102.27%
4/27/2020LADENBURG THALM/SH SH
Boost Price TargetPositive ➝ Buy$165.00 ➝ $186.00+91.40%
4/27/2020SunTrust Banks
Boost Price TargetPositive ➝ Buy$145.00 ➝ $200.00+112.98%
4/14/2020Cowen
Initiated CoverageOutperform$95.00+58.23%
12/16/2019Piper Jaffray Companies
Danielle Brill
Reiterated RatingBuy$125.00+56.64%
(Data available from 9/24/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings Frequently Asked Questions

What is Axsome Therapeutics's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 sell rating, 1 hold rating and 11 buy ratings for AXSM. The average twelve-month price target for Axsome Therapeutics is $103.65 with a high price target of $180.00 and a low price target of $34.00. Learn more on AXSM's analyst rating history

Do Wall Street analysts like Axsome Therapeutics more than its competitors?

Analysts like Axsome Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Axsome Therapeutics is 2.77 while the average consensus rating score for medical companies is 2.73. Learn more on how AXSM compares to other companies

Do MarketBeat users like Axsome Therapeutics more than its competitors?

MarketBeat users like Axsome Therapeutics stock more than the stock of other Medical companies. 71.54% of MarketBeat users gave Axsome Therapeutics an outperform vote while medical companies recieve an average of 67.42% outperform votes by MarketBeat users.

Is Axsome Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Axsome Therapeutics's stock had 1 downgrade by analysts.

Does Axsome Therapeutics's stock price have much upside?

According to analysts, Axsome Therapeutics's stock has a predicted upside of 140.96% based on their 12-month price targets.

What analysts cover Axsome Therapeutics?

Axsome Therapeutics has been rated by BTIG Research, HC Wainwright, Mizuho, Morgan Stanley, SVB Leerink, Truist, Truist Securities, and William Blair in the past 90 days.

This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.